Loading the session
Loading the session
Loading instrument
$21.26
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
7.3M shares were sold short at the 15 Oct 2026 settlement, 10.1% of the 72.2M shares outstanding; covering them would take 10.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: +2.1% (SPY −1.6%, XLV +13.5%). 3 months: +3.7% (SPY −0.4%, XLV +15.5%). 1 year: +17.1% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: INVA, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $21.26 was 1.3% above its 50-day average ($20.99) and 3.0% below its 200-day average ($21.91). It has closed below the 200-day for 69 sessions, since 30 Jul 2026. The 50-day average crossed below the 200-day on 24 Aug 2026, 51 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $21.26 on 4 Nov 2026: 15.5% below the 52-week high of $25.15 (26 Feb 2026) and 12.8% above the low of $18.85 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
November 6, 2025
+12.89%March 3, 2022
−7.83%February 10, 2022
+13.71%